How to treat bone metastases from prostate cancer?

Written by Zhou Zi Hua
Oncology
Updated on September 24, 2024
00:00
00:00

The treatment of bone metastases from prostate cancer can include first-line hormonal therapy. During hormonal treatment, bisphosphonates can be used in conjunction to increase bone density. Additionally, external radiation therapy can improve localized bone pain. Patients with multiple bone metastases or bone pain can undergo radionuclide therapy. Another method is the use of analgesic drug therapy, which is also a main approach to alleviate pain from bone metastases of prostate cancer.

Other Voices

doctor image
home-news-image
Written by Cui Fang Bo
Oncology
38sec home-news-image

Prostate cancer IV is stage 4.

Prostate cancer stage IV refers to stage four prostate cancer, which is a common type of male reproductive organ tumor, particularly prevalent among elderly men. Stage four prostate cancer means that the tumor is not confined to the prostate and has already shown corresponding distant metastasis. The most common sites of metastasis for prostate cancer are the bones, followed by the lungs, liver, and others. When metastasis of prostate cancer occurs, it is considered to be at a late stage, and the primary treatments include endocrine therapy, chemotherapy, etc., with a poor prognosis.

doctor image
home-news-image
Written by Zhou Zi Hua
Oncology
34sec home-news-image

How to treat bone metastases from prostate cancer?

The treatment of bone metastases from prostate cancer can include first-line hormonal therapy. During hormonal treatment, bisphosphonates can be used in conjunction to increase bone density. Additionally, external radiation therapy can improve localized bone pain. Patients with multiple bone metastases or bone pain can undergo radionuclide therapy. Another method is the use of analgesic drug therapy, which is also a main approach to alleviate pain from bone metastases of prostate cancer.

doctor image
home-news-image
Written by Zhou Zi Hua
Oncology
51sec home-news-image

Endocrine therapy after radical prostatectomy for prostate cancer

Endocrine therapy after radical prostatectomy for prostate cancer is equivalent to adjuvant endocrine therapy for prostate cancer. Its purpose is to treat residual lesions, positive residual lymph nodes, and microscopic metastatic foci, thereby improving long-term survival rates. Currently, the indications for adjuvant endocrine therapy are based on postoperative pathology-positive results, positive lymph nodes post-surgery, and postoperative pathology confirmation of stage T3 or T4, but with high-risk factors. According to major guidelines, the duration of adjuvant endocrine therapy should be at least eighteen months.

doctor image
home-news-image
Written by Zhou Zi Hua
Oncology
1min home-news-image

Pathological classification of prostate cancer

The classification of precancerous lesions of prostate cancer is divided into two categories: intraductal carcinoma of the prostate and atypical adenomatous hyperplasia. Among these, the relationship between intraductal carcinoma of the prostate and prostate cancer is the closest. Intraductal carcinoma of the prostate is currently recognized as a precancerous lesion of prostate cancer, while atypical adenomatous hyperplasia has not been proven to be a precancerous lesion of prostate cancer according to current evidence. However, the biological behavior of this atypical adenomatous hyperplasia is not very clear yet, so it should be closely monitored. The histological classification of prostate cancer mainly includes the majority of acinar adenocarcinoma and a small amount of ductal adenocarcinoma, with acinar adenocarcinoma being a highly invasive malignant tumor.

doctor image
home-news-image
Written by Zhou Zi Hua
Oncology
57sec home-news-image

Commonly used drugs for endocrine treatment of prostate cancer

The purpose of endocrine therapy for prostate cancer is to reduce the concentration of androgens in the body, inhibit the synthesis of androgens originating from the adrenal glands, inhibit the conversion of testosterone to dihydrotestosterone, or block the binding of androgens to their receptors, thereby inhibiting or controlling the growth of prostate cancer cells. The medications include a luteinizing hormone-releasing hormone analogue, with representative drugs being leuprorelin, goserelin, and triptorelin. There is also an androgen-blocking drug, including steroidal drugs with representative drugs like cyproterone acetate, and non-steroidal drugs with representative drugs like bicalutamide and flutamide. Additionally, there are estrogens, with the most common being diethylstilbestrol.